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Parkinson’s disease (PD) is the most common motor disorder
affecting the elderly. PD is characterized by the formation of Lewy
bodies and death of dopaminergic neurons. The mechanisms
underlying PD are unknown, but the discoveries that mutations in
a-synuclein can cause familial PD and that a-synuclein accumu-
lates in Lewy bodies suggest that a-synuclein participates in the
pathophysiology of PD. Using human BE-M17 neuroblastoma
cells overexpressing wild-type, A53T, or A30P a-synuclein, we
now show that iron and free radical generators, such as dopa-
mine or hydrogen peroxide, stimulate the production of intracel-
lular aggregates that contain a-synuclein and ubiquitin. The ag-
gregates can be identified by immunocytochemistry, electron
microscopy, or the histochemical stain thioflavine S. The amount
of aggregation occurring in the cells is dependent on the amount
of a-synuclein expressed and the type of a-synuclein expressed,
with the amount of a-synuclein aggregation following a rank
order of A53T . A30P . wild-type . untransfected. In addition
to stimulating aggregate formation, a-synuclein also appears to
induce toxicity. BE-M17 neuroblastoma cells overexpressing
a-synuclein show up to a fourfold increase in vulnerability to
toxicity induced by iron. The vulnerability follows the same rank
order as for aggregation. These data raise the possibility that
a-synuclein acts in concert with iron and dopamine to induce
formation of Lewy body pathology in PD and cell death in PD.
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Parkinson’s disease (PD) is a common neurodegenerative disorder.
The four primary diagnostic signs of the illness are resting tremor,
bradykinesia, muscular rigidity, and postural instability. These
signs of motor deficiency result from the loss of dopaminergic
neurons in the nigrostriatal system (Gibb and Lees, 1988). The
neuropathological hallmark of PD is the Lewy body. Lewy bodies
are intracytoplasmic inclusions that occur in degenerating neurons,
which are composed of a dense core of filamentous and granular
material surrounded by radially oriented filaments that have a
diameter of 10–20 nm (Goedert et al., 1999). In general, the causes
of PD are not known, and there has been vigorous debate over the
relative roles of genetics and environmental factors (Tanner et al.,
1999). The only defined causes of the disease are A53T and A30P
mutations in the a-synuclein gene (Polymeropoulos et al., 1997;
Goedert et al., 1999; Papadimitriou et al., 1999), but there has been
much circumstantial evidence implicating oxidative stress in the
etiology of the disease (Jenner and Olanow, 1998). Immunohisto-
chemical studies indicate that Lewy bodies stain strongly for
a-synuclein and ubiquitin (Spillantini et al., 1997; Jenner and
Olanow, 1998; Spillantini et al., 1998; Markopoulou et al., 1999).
The mechanisms by which mutations in a-synuclein lead to PD are
unknown. One study suggest that the mutations might reduce
a-synuclein expression (Markopoulou et al., 1999). However, most
in vitro experiments using recombinant protein suggest that the
mutations lead to increases in a-synuclein aggregation because of
an increase in the rate of aggregation of mutant A53T and A30P
proteins compared with wild-type a-synuclein (Conway et al., 1998;
Hashimoto et al., 1998; Giasson et al., 1999). These findings suggest
that increased rate of a-synuclein aggregation might contribute to
the mechanisms of neurodegeneration in PD.
Recently, oxidative stress produced by iron and hydrogen per-
oxide has been shown to induce amyloid-like aggregate formation
of a-synuclein in vitro (Hashimoto et al., 1999; Paik et al., 1999).
Oxidative stress is thought to contribute to PD because dopamine,
which is a strong free radical generator, is the principle neurotrans-
mitter in the substantia nigra (Chiueh et al., 1993; Jenner and
Olanow, 1998). In addition, iron, which also stimulates free radical
production, accumulates in the substantia nigra with age (Jenner
and Olanow, 1998). Thus, the oxidative conditions present in the
substantia nigra could promote a-synuclein aggregation. Whether
such oxidative conditions actually promote a-synuclein aggregation
in living neurons, however, is unknown.
MATERIALS AND METHODS
Materials. a-Synuclein (wild-type, A53T, and A30P) was cloned into the
NotI site of pcDNA3. The sequence of each construct was confirmed by
DNA sequencing. For production of recombinant protein, a-synuclein was
inserted into the NcoI /NotI site of the Pro-Ex His-6 vector (Life Technol-
ogies, Gaithersburg, MD). To generate recombinant a-synuclein, BPer
(Pierce, Rockford, IL) reagent was used to solubilize the recombinant
a-synuclein from the isopropylthio-b-D-galactoside-induced bacterial ly-
sates, which were then passed over a nickel-agarose affinity column,
washed, and eluted with imidazole according to the directions of the
manufacturer (Life Technologies). After purification, the His-6 tag was
cleaved with tobacco etch virus protease and removed by passing through
a nickel-agarose column. Antibodies used include the following: polyclonal
anti-a-synuclein (SC1; 1:2000 for immunoblotting and 1:500 for immuno-
cytochemistry against human a-synuclein; residues 116–131; sequence,
MPVDPDNEAYEMPSEE), monoclonal anti-a-synuclein-1 (1:1000;
Transduction Laboratories, Lexington, KY), and polyclonal rabbit anti-
ubiquitin (1:1000 for immunoblotting and 1:500 for immunocytochemistry;
Dako, High Wycombe, UK).
Cell culture. Cells were grown in OPTIMEM (Life Technologies) sup-
plemented with 10% FBS, nonessential amino acids, sodium pyruvate, and
500 mg/ml G418, as needed. G418 was used for selection.
Immunoblotting. Cells were harvested with SDS lysis solution [2% SDS,
10 mM Tris, pH 7.4, 2 mM b-glycerol phosphate, and 1 mM 4-(2-
aminoethyl)benzenesulfonyl fluoride hydrochloride]. The amount of pro-
tein was determined using the BCA assay (Pierce); 5–30 mg/ lane was run
on 14% SDS polyacrylamide gels and transferred to nitrocellulose (200
mA, 12 hr). The nitrocellulose was then incubated 1 hr in 5% milk–PBS,
washed, incubated overnight in 1° antibody, washed, then incubated 3 hr in
peroxidase-coupled 2° antibody, and developed with chemiluminescent
reagent (NEN, Boston, MA).
Cell f ractionation. For cell fractionation, the cells were harvested in
buffer containing 20 mM Tris, pH 7.4, 2 mM EDTA, 0.25 M sucrose, and 20
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mg/ml protease inhibitor cocktail (Sigma, St. Louis, MO). The cell lysate
was sonicated and centrifuged at 100,000 3 g at 4°C for 1 hr.
MTT and lactate dehydrogenase toxicity assay. Cells were plated in 96 well
dishes at 5000 cells per well in 100 ml of growth medium. For the MTT
assay, viability after 48 hr of pharmacological treatment was analyzed by
adding 0.5 mg/ml MTT and incubating at 37°C for 3 hr. Lysis buffer (100
ml of 20% SDS in 50% N, N-dimethylformamide) was then added, and the
plates are read at 540 nm after 24 hr. For the lactate dehydrogenase (LDH)
assay, viability after 24 hr of pharmacological treatment was analyzed using
MTS reagent and the Cytox 96 kit (Promega, Madison, WI) according to
the directions of the manufacturer.
Thioflavine S histochemistry. Cells were fixed 30 min in 4% paraformal-
dehyde. After two PBS washes, the cells were incubated with 0.5% thio-
flavine S for 8 min, washed three times in 80% ethanol, washed once in
H2O, and then mounted.
Electron microscopy. Cells were detached by scraping, spun down, fixed
in 2% glutaraldehyde for 2 hr at 4°C, and then post-fixed in 1% osmium
tetroxide for 1 hr at 4°C. The samples were dehydrated, embedded in epoxy
resin (Electron Microscopy Sciences, Fort Washington, PA), and cut into
70 nm sections for microscopy. The sections were then post-stained with
5% uranyl acetate and Reynolds lead citrate. Samples were viewed with a
Hitachi H-600 transmission electron microscope at 75 kV.
Iron staining. Cells were fixed 30 min in 4% paraformaldehyde, followed
by two PBS washes, and stained using the Accustain Iron Stain according
to the directions of the manufacturer (Sigma).
Immunohistochemistry. For light microscopy, cells were fixed with 4%
paraformaldehyde, washed, permeabilized by incubation for 30 min with
0.2% Triton X-100, blocked with 5% dry milk–1% goat serum–PBS,
washed, and then incubated overnight in 1° antibody (1:500). Development
was with an ABC kit and 39,39-diaminobenzidine as per the directions of
the manufacturer (Vector Laboratories, Burlingame, CA).
RESULTS
Iron and free radicals stimulate a-synuclein aggregation
To test whether A53T and A30P mutations in a-synuclein increase
the tendency of a-synuclein to aggregate in neurons, we examined
a-synuclein aggregation in human BE-M17 neuroblastoma cells
stably transfected with wild-type, A53T, or A30P a-synuclein (Fig.
1A). Each cell line was treated for 48 hr with freshly prepared
FeCl2 (1 or 10 mM) and then harvested, homogenized, and frac-
tionated into membrane and cytoplasmic components. The mem-
brane (5 mg/ lane) and cytoplasmic (20 mg/ lane) components were
immunoblotted with monoclonal anti-a-synuclein antibody. Aggre-
gates of a-synuclein were evident in the membrane fraction but not
in the cytoplasmic fraction (Fig. 1, membrane fraction shown).
Treatment of the A53T-expressing cell line with FeCl2 induced
dose-dependent formation of heterogeneous high molecular weight
a-synuclein aggregates that migrated in the stacking gel (Fig. 1B,
solid bracket). A large amount of anti-a-synuclein immunoreactiv-
ity was also apparent in the upper portions of the separating gel, in
the range of 45–200 kDa (Fig. 1B, lane 2, dotted bracket). Because
these bands are significantly larger than monomeric a-synuclein,
which has a mass of 19 kDa, these bands might also represent
a-synuclein polymers and aggregates. For instance, the bands at 38
and 57 kDa have sizes consistent with dimers and trimers of
a-synuclein. Immunoblots done with a different antibody, a poly-
clonal anti-a-synuclein antibody, also showed aggregate production
under the same conditions (data not shown). Treatment of the
other cell lines (untransfected, wild-type, and A30P) did not induce
a-synuclein aggregates within the 48 hr time frame examined (data
not shown).
To determine whether increasing the duration of exposure to
iron produced aggregation of a-synuclein at lower doses of iron, we
exposed BE-M17 cells overexpressing A53T or wild-type
a-synuclein to FeCl2 for 4 d. Under these conditions, doses as low
as 0.3 mM FeCl2 produced detectable aggregation of a-synuclein in
cells expressing A53T a-synuclein (Fig. 1C, lef t panel). Interest-
ingly, these longer conditions also induced aggregation of wild-type
a-synuclein (Fig. 1C, middle panel). In contrast, no aggregation of
actin was observed, which suggests that aggregation is selective for
a-synuclein (Fig. 1C, right panel). We also examined whether
Bcl-2-associated death protein (BAD) aggregated, because BAD is
a pro-apoptotic protein that binds to a-synuclein (Osterova et al.,
1999). However, no aggregated BAD reactivity was apparent (data
not shown).
To understand how the pattern of a-synuclein aggregation in the
BE-M17 cells compares with that occurring in human brain, we
investigated the response of a-synuclein in human cortical brain
homogenates (from a neurologically normal donor) to iron expo-
sure in vitro. The pattern of a-synuclein aggregation in the mem-
brane fraction of the cortical brain homogenate after treatment for
24 hr with 500 mM dopamine, 10 mM FeCl2, and protease inhibitors
(dopamine was added as an oxidant, as described below) was
similar to that seen in the BE-M17 cells. This suggests that
a-synuclein in BE-M17 cells and in human brain exhibit similar
aggregation patterns in response to iron, and both share a strong
tendency to aggregate.
In the course of our investigations, we noted that higher molec-
ular weight a-synuclein immunoreactivity occasionally appeared in
separating gels of immunoblots of a-synuclein cell lysates from
cells grown under basal conditions (Fig. 1C). However, aggregates
that migrated in the stacking gel only occurred after treatment with
iron and were never observed in any of the cell lines under basal
conditions. This supports previous work done with recombinant
a-synuclein in vitro indicating that the mutant forms of a-synuclein
have a strong tendency to oligomerize (Conway et al., 2000). How-
ever, migration of aggregates in the stacking gel might be a stricter
test of aggregate formation than migration in the separating gel.
Iron might promote protein aggregation by increasing free rad-
ical formation through the Fenton reaction (Wolozin and Behl,
2000). If so, then adding free radical generators, such as hydrogen
peroxide or dopamine, along with the iron might increase the
amount of a-synuclein aggregation. To test whether oxidation
enhanced iron-induced aggregation of a-synuclein, we treated BE-
M17 cells overexpressing A30P or wild-type a-synuclein for 48 hr
with 10 mM FeCl2 plus varying concentrations of dopamine (Fig.
2A, A30P overexpressing cells shown). We used cells expressing
A30P or wild-type a-synuclein over 48 hr because they do not form
Figure 1. Iron stimulates a-synuclein aggregation. A, Immunoblot of
a-synuclein in cell lines overexpressing wild-type (WT ), A53T, and A30P
a-synuclein using the monoclonal anti-a-synuclein antibody (top). The
same immunoblot was then stripped and reprobed with antibody to actin.
UT, Untransfected. B, Aggregation of a-synuclein in BE-M17 cells express-
ing A53T a-synuclein after treatment with 1 or 10 mM FeCl2 for 48 hr (in
each panel, the solid bracket shows putative aggregates in the stacking gel,
and the dotted bracket shows putative aggregates in the separating gel). C,
Longer exposure (4 d) enabled lower doses of FeCl2 to induce aggregation
of a-synuclein BE-M17 cells expressing A53T a-synuclein (lef t) or wild-
type a-synuclein (middle). Under these conditions, little or no aggregation
of actin was observed (right). D, In vitro analysis of a-synuclein aggregation.
Immunoblotting of a-synuclein in brain membrane fractions under basal
conditions (lane 1) or after treatment with 10 mM FeCl2 and 500 mM
dopamine (DA) for 24 hr (lane 2) shows the induction of high molecular
weight aggregates similar to that seen in the BE-M17 cells.
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aggregates under these conditions, unlike cells overexpressing
A53T a-synuclein. As expected, BE-M17 cells overexpressing
A30P or wild-type a-synuclein treated with 10 mM FeCl2 alone did
not induce any aggregation (Fig. 2A, lane 2). Similarly, treatment
with 5, 50, or 500 mM dopamine alone did not induce formation of
large a-synuclein aggregates that migrate in the stacking gel (Fig.
2A, lanes 3, 5, 7). However, combining 10 mM FeCl2 with 50 or 500
mM dopamine induced formation of large a-synuclein aggregates
(Fig. 2A, lanes 6, 8). These data show that the combination of
oxidants and iron can exert additive effects on a-synuclein
aggregation.
Two separate experiments indicated that the aggregation ob-
served was a general property of a-synuclein rather than an artifact
resulting from use of clonal cell lines. BE-M17 cells that were
transiently transfected with A53T a-synuclein cDNA and then
treated with 10 mM FeCl2 plus 100 mM H2O2 for 72 hr developed
aggregates similar to those seen in the BE-M17 cell lines stably
overexpressing a-synuclein (data not shown). In addition, primary
rat cortical neurons also showed a strong tendency to develop
aggregates, requiring only 60 hr of treatment with 0.1 mM FeCl2
and 50 mM dopamine to induce formation of aggregates (Fig. 2C).
Thus, the aggregation was a result of a biophysical property of
a-synuclein rather than being an artifact specific to particular
clonal cell lines.
A53T and A30P a-synuclein aggregates
contain ubiquitin
In PD, Lewy bodies have also been shown to contain large amounts
of ubiquitin (Gibb and Lees, 1988; Dickson et al., 1999). The
presence of ubiquitin in Lewy bodies prompted us to examine
whether aggregation of ubiquitin also occurred along with
a-synuclein aggregation. We took lysates (membrane fractions)
from the BE-M17 cells expressing A30P a-synuclein that had been
treated with FeCl2 and dopamine (Fig. 2A) and immunoblotted
them with anti-ubiquitin antibody (Fig. 2B). The ubiquitin aggre-
gates that accumulated under these conditions stained strongly for
ubiquitin (Fig. 2A,B). Aggregates that accumulated in cells ex-
pressing A53T a-synuclein or wild-type a-synuclein after being
treated with FeCl2 alone, FeCl2 plus hydrogen peroxide, or FeCl2
plus dopamine also contained ubiquitin (data not shown). In many
cases, ubiquitin appeared to be a more sensitive indicator of ag-
gregation on the immunoblots than a-synuclein (Fig. 2B). The
amount of aggregated ubiquitin generally paralleled the amount of
a-synuclein (Fig. 2A,B). The presence of ubiquitin in aggregates
did not appear to result from increased ubiquitin expression be-
cause immunoblots of total lysates showed that the total amount of
ubiquitin and actin did not different significantly between cell lines
overexpressing a-synuclein and control cells. These data suggest
that aggregates of a-synuclein that form in neurons in response to
iron treatment are ubiquinated.
a-Synuclein aggregates form visible inclusions evident
by thioflavine S histochemistry and electron microscopy
Next, we used thioflavine S histochemistry and electron microscopy
to examine the aggregates that formed in response to treatment
with iron and hydrogen peroxide. We treated cells from each line
(BE-M17: untransfected, wild-type, A30P, and A53T a-synuclein)
with 10 mM FeCl2 or 10 mM FeCl2 plus 100 mM H2O2 for 72 hr to
induce formation of a-synuclein-positive inclusions. The aggre-
gates that formed were observed to bind thioflavine S, which
indicates the presence of b-pleated sheet structures (Fig. 3). The
size and number of thioflavine S-positive aggregates paralleled the
results seen by immunoblotting. The wild-type, A30P, and A53T
a-synuclein cell lines each showed significant accumulations of
protein aggregates after treatment for 72 hr with 10 mM FeCl2 plus
100 mM H2O2 (Fig. 3A,B). In contrast, the untransfected line
showed no accumulation of thioflavine S-positive aggregates (Fig.
3C). When only 10 mM FeCl2 was used to treat the cells, shown
thioflavine S-positive inclusions were observed only in A53T
a-synuclein-expressing cells (Fig. 3D–F).
Next, we used electron microscopy to examine the aggregates.
Cells expressing A53T a-synuclein or empty vector were treated
with 10 mM FeCl2 plus 100 mM H2O2 for 72 hr and then prepared
for electron microscopy. Cytoplasmic inclusions were apparent in
the A53T-expressing cells but not in the vector-transfected cells
(Fig. 3G,H). The inclusions contained mixtures of fibrillar and
amorphous material (Fig. 3G). The fibrils had an approximate
diameter of 10 nm and a length of up to 10 mm. The presence of
both fibrillar and amorphous material in the aggregates has been
observed in aggregates present in transgenic animals overexpress-
ing a-synuclein (Feany and Bender, 2000; Masliah et al., 2000).
a-Synuclein aggregates form visible inclusions evident
by immunohistochemistry
We also examined the inclusion formation by immunocytochemis-
try. Cells expressing A53T a-synuclein were treated with 10 mM
FeCl2 plus 100 mM H2O2 for 72 hr, fixed, and then examined with
antibodies to ubiquitin and a-synuclein using peroxidase immuno-
histochemistry. We used peroxidase staining because fluorescent
Figure 2. Free radicals potentiate induction of a-synuclein aggregation by
iron. A, B, Aggregation of a-synuclein in BE-M17 cells expressing A30P
a-synuclein after treatment with 0, 5, 50, and 500 mM dopamine plus or
minus 10 mM FeCl2 for 48 hr. The immunoblot was first probed with
monoclonal anti-synuclein antibody (A) and then reprobed with anti-
ubiquitin antibody (B). C, Immunoblots of lysates from primary cortical
neurons after treatment with 0, 0.1, or 10 mM FeCl2 and 50 mM dopamine
(DA) for 60 hr.
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chromagens, such as FITC or rhodamine, exhibited strong nonspe-
cific binding to the cells because of the treatment with iron.
Immunohistochemistry with both the anti-a-synuclein and anti-
ubiquitin antibodies showed uniform staining throughout the cyto-
plasm of the cells under basal conditions (Fig. 4A,B). After treat-
ment with 10 mM FeCl2 plus 100 mM H2O2 for 72 hr, the staining
became less uniform. Cells stained with anti-a-synuclein antibody
often displayed several large darkly stained reactive foci and mul-
tiple small punctate foci in each cell (Fig. 4C). Staining with
ubiquitin was also present but showed foci per cell (Fig. 4D).
Immunocytochemistry performed with the preimmune rabbit se-
rum instead of primary antibody showed no reactivity under either
basal or treated conditions (Fig. 4E,F).
a-Synuclein aggregation occurs in viable cells
Treating cells with FeCl2 can be toxic, and it is possible that
aggregation of a-synuclein occurs after cell death. To determine
the relationship between a-synuclein aggregation and cell death,
we examined aggregate formation and cell viability in the presence
of high and low concentrations of FeCl2. As described above (Figs.
3, 4), treatment with 10 mM FeCl2 plus 100 mM H2O2 for 72 hr
induced formation of a-synuclein aggregates in most cells; how-
ever, these conditions also were observed to kill most of the cells
(.90% cell death).
In contrast, A53T-expressing BE-M17 cells treated with 0.3 mM
FeCl2 plus 100 mM H2O2 for 96 hr exhibited much less toxicity, yet
still formed a-synuclein aggregates. Parallel sets of cells were
processed for immunocytochemistry with antibodies to a-synuclein
(SC1) and ubiquitin or were processed to measure viability using
the trypan blue exclusion assay. Untreated cells showed little tox-
icity, with 3.7 6 1.0% being permeable to trypan blue (Fig. 5). The
small amount of cell death present might have been caused by the
trypsinization–trituration step used to dislodge the cells. Treat-
ment with 0.3 mM FeCl2 with or without 100 mM H2O2 killed some
cells (12.1 6 2.3% trypan blue-positive), but the large majority of
cells (87.9%) remained viable (Fig. 5A). Immunocytochemistry
with anti-a-synuclein antibody showed that 21.0 6 3.5% of the cells
had visible aggregates (Fig. 5B). Immunocytochemistry with anti-
ubiquitin antibody suggested that the aggregates could contain
ubiquitin (Fig. 5C) and that the aggregates contained material that
had a b-pleated sheet structure that stained with thioflavine S (Fig.
5D). Interestingly, diffuse thioflavine S reactivity was also evident
in these cells, suggesting that dispersed “micro-aggregates” of
a-synuclein might also form under the mild conditions.
Thus, the a-synuclein aggregates that formed under mild condi-
tions reacted with the same antibodies and stains as aggregates that
formed under harsher conditions. Moreover, the observation that
the percentage of cells displaying a-synuclein aggregates was
greater than the percentage of cells showing evidence of death
suggests that many of the cells developing a-synuclein aggregates
are viable. The observation that aggregation of a-synuclein can
occur in viable cells also suggests that aggregation of a-synuclein
precedes cell death.
Overexpression of a-synuclein increases free
radical-mediated toxicity
Despite the fact that a-synuclein aggregates can form in viable
cells, it is possible that aggregation of a-synuclein might represent
an initial step in the induction of toxicity. Our previous results show
that a-synuclein is toxic to some cells when transiently overex-
pressed (Ostrerova et al., 1999). However, a-synuclein is not
acutely toxic to all cells. a-Synuclein is not acutely toxic to BE-M17
cells (data not shown), and a-synuclein is tolerated well enough to
allow overexpression in transgenic animals (Feany and Bender,
2000; Masliah et al., 2000). Although a-synuclein is not acutely
toxic to BE-M17 cells under basal conditions, we hypothesized that
a-synuclein might be toxic under other conditions, such as condi-
tions linked to formation of aggregates.
To determine whether conditions that produce a-synuclein ag-
gregation also produce toxicity, we examined the vulnerability of
each cell line to iron- and/or hydrogen peroxide-mediated toxicity.
Each cell line (untransfected, wild-type, A53T, and A30P
a-synuclein) was treated with varying doses of FeCl2, H2O2, or
FeCl2 plus H2O2, and the amount of toxicity was determined by
MTT assay. BE-M17 cells overexpressing all forms of a-synuclein
showed increased vulnerability to iron-mediated toxicity (Fig. 6A).
Overexpression of A53T a-synuclein had the greatest effect on
toxicity, reducing the LD50 of FeCl2 over 75% (Fig. 6A). Overex-
pression of A30P or wild-type a-synuclein constructs reduced the
LD50 values by ;50%, although the amount of toxicity seen in
Figure 3. Identifcation of a-synuclein aggregates by thioflavine S staining and by electron microscopy. A–C, Treatment of cells expressing A53T
a-synuclein (A), wild-type a-synuclein (B), or untransfected cells (C) with 10 mM FeCl2 and 100 mM H2O2 for 72 hr. D–F, Treatment of cells expressing
A53T a-synuclein (D), wild-type a-synuclein (E), or untransfected cells (F) with 10 mM FeCl2 for 72 hr. G, H, Inclusions are evident by electron
microscopy. BE-M17 cells stably transfected with A53T a-synuclein were treated with 10 mM FeCl2 and 100 mM H2O2 for 72 hr and then examined by
electron microscopy. The aggregates that formed under these conditions were long fibrils with a diameter of ;10 nm (G, magnification of 35,0003).
Although treatment with 10 mM FeCl2 and 100 mM H2O2 was toxic to many cells, some cells containing aggregates had both fibrillar deposits (triangle)
and organelles that were intact (arrow), suggesting that aggregation can occur in living cells (H, magnification of 20,0003). Arrows point to thioflavine
S-positive aggregates.
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A30P-expressing cells in response to low levels of iron was gener-
ally greater than toxicity seen with wild-type a-synuclein (Fig. 6A).
To confirm that overexpression of a-synuclein increased the vul-
nerability of the neuroblastoma cells to iron, we also examined
iron-induced toxicity using an LDH assay (Fig. 6B). The LDH
assay confirmed that overexpression of the a-synuclein constructs
increases iron-induced toxicity (Fig. 6B). MTT assays of cell lines
overexpressing a-synuclein (wild-type, A53T, or A30P) also re-
vealed increased toxicity after treatment with FeCl2 plus H2O2
(Fig. 6C, dark gray bars). Interestingly, overexpressing a-synuclein
(wild-type, A53T, or A30P) did not increase the vulnerability to
H2O2 alone and conferred modest protection to the neuroblastoma
cells (Fig. 6C). These data demonstrate that increased levels of
either wild-type or mutant a-synuclein can be toxic to neurons
grown in cell culture under selective conditions. The data suggest
that a-synuclein renders the cells particularly vulnerable to iron-
mediated toxicity. The selective vulnerability to iron could result
from a tendency of a-synuclein to sequester iron in a-synuclein
aggregates. To test this, we treated untransfected or A53T
a-synuclein-expressing BE-M17 cells with 10 mM FeCl2 and 100
mM H2O2 for 48 hr, fixed them, and then stained the cells for iron.
The cells expressing A53T a-synuclein had a much higher iron
content than the untransfected cells after treatment (Fig. 6D).
Sequestration of iron attributable to a-synuclein would increase
free radical production via the Fenton reaction, particularly in cells
exposed to free radical generators, such as hydrogen peroxide or
dopamine. However, in the absence of iron, no Fenton reaction
occurs and the a-synuclein is innocuous.
Figure 4. Identification of a-synuclein aggregates by immunocytochemis-
try. A, B, Under basal conditions, BE-M17 cells overexpressing A53T
a-synuclein showed diffuse cytoplasmic staining with antibodies to
a-synuclein (A) and ubiquitin (B). C, D, Treatment with 10 mM FeCl2 and
100 mM H2O2 for 72 hr induced formation of aggregates, which stained
positive using antibodies to a-synuclein (C) and ubiquitin (D). Arrows point
to some of the labeled inclusions. E, In contrast, cells treated with 10 mM
FeCl2 and 100 mM H2O2 for 72 hr and stained with preimmune serum
showed very little reactivity. F, Untreated cells also showed no reactivity
with preimmune serum.
Figure 5. a-Synuclein aggregation can occur in viable cells. BE-M17 cells
overexpressing A53T a-synuclein were treated with 0.3 mM FeCl2 with or
without 100 mM H2O2 for 96 hr. A, Comparison of cell death and aggregate
formation in cells expressing A53T a-synuclein. Cell viability measure-
ments were based on a trypan blue exclusion assay, and a-synuclein aggre-
gates were identified by immunocytochemistry using the anti-a-synuclein
SC1 antibody. The cell death determinations were based on quantitation of
three different samples of treated and untreated cells. Quantitation of
aggregates was based on counting the number of cells containing
a-synuclein aggregates in five microscopy fields chosen at random for
treated and untreated cells. *p , 0.05, **p , 0.001. B, C, Immunocyto-
chemistry of A53T a-synuclein cells treated with 0.3 mM FeCl2 with or
without 100 mM H2O2 for 96 hr. B shows aggregates that were positive for
a-synuclein (SC1 antibody), and C shows aggregates that were positive for
ubiquitin (anti-ubiquitin antibody). D, A53T a-synuclein cells under basal
conditions show little staining with thioflavine S. E, Treating A53T
a-synuclein cells with 0.3 mM FeCl2 for 4 d induced formation of inclusions
that could be stained with thioflavine S. Arrows point to some of the
thioflavine S-positive inclusions. In addition, treated cells (E) stained much
stronger with thioflavine S than untreated cells ( D).
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DISCUSSION
a-Synuclein has gained prominence because mutations in
a-synuclein cause familial PD in several kindreds and because the
protein accumulates in Lewy bodies (Goedert et al., 1999). In vitro
studies using recombinant a-synuclein show that the protein has a
strong tendency to aggregate and that the A53T and A30P muta-
tions increase the rate of aggregation (Conway et al., 1998; Hashi-
moto et al., 1998; Giasson et al., 1999). We have now shown that
a-synuclein also forms aggregates in neurons when cells are ex-
posed to iron or iron plus either hydrogen peroxide or dopamine,
which generate free radicals. Moreover, we observe that the A53T
a-synuclein mutation shows an increased tendency to form aggre-
gates, which is consistent with observations in vitro (Conway et al.,
1998, 2000; Hashimoto et al., 1998; Giasson et al., 1999). The
aggregates also contain ubiquitin, which is known to be a major
component of Lewy bodies. Equally striking is the fact that aggre-
gation is largely restricted to a-synuclein, as shown by the obser-
vation that actin does not aggregate under these conditions. Cell
toxicity per se does not appear to cause aggregation because
treatment with dopamine alone, which causes toxicity, does not
induce a-synuclein aggregation. On the other hand, treating cells
with iron does induce a-synuclein aggregation, and overexpressing
a-synuclein sensitizes cells to iron-mediated toxicity. Thus, there
appears to be a linkage between toxicity, aggregation, iron, and
a-synuclein. We propose that aggregation of a-synuclein increases
cellular iron content, which increases oxidative toxicity. Thus, the
interaction between a-synuclein and iron might be a critical, and
causal, step in the pathophysiology of Parkinson’s disease.
Our results implicate iron in the pathophysiology of a-synuclein.
Exposure of the cells to iron plus other free radical generators,
such as dopamine or hydrogen peroxide, was able to induce
a-synuclein aggregation in all of the cell lines. On the other hand,
exposure of cells to dopamine alone did not induce aggregation.
These results point to the important role that iron plays in inducing
a-synuclein aggregation. In the presence of iron, concentrations of
dopamine as low as 5 mM induce aggregation of all forms of
a-synuclein (wild-type, A30P, and A53T), which is within the range
of dopamine that is thought to be present in the neurons of the
substantia nigra.
There is a large amount of circumstantial evidence implicating
oxidative factors, especially iron, in both the etiology and patho-
genesis of PD and other diseases that exhibit aggregated
a-synuclein, such as multiple systems atrophy (Koga et al., 1998;
Martin et al., 1998; Dickson et al., 1999). Because iron-induced
a-synuclein aggregation is dose-dependent, the accumulation of
iron in the substantia nigra that occurs during aging or Lewy body
disease might increase the rate of aggregation of a-synuclein. In
fact, iron has been shown recently to be present in Lewy bodies in
the substantia nigra (Castellani et al., 2000). The presence of
dopamine combined with the accumulation of iron substantia nigra
of elderly subjects might therefore promote the aggregation of
a-synuclein and formation of Lewy bodies.
Lewy bodies also contain a large amount of ubiquitin (Leroy et
al., 1998). Our studies revealed that the aggregates formed in the
BE-M17 cells in response to the conditions that produced
a-synuclein aggregation also contain ubiquitin. The amount of
ubiquitin protein that accumulated in the aggregates appeared to
be proportional to the amount of a-synuclein aggregation. This
suggests that the process of a-synuclein aggregation is coupled to
ubiquitination. Many studies have observed that both a-synuclein
and ubiquitin are abundant in Lewy bodies and other types of
a-synuclein pathology (Spillantini et al., 1997, 1998; Masliah et al.,
2000). Whether ubiquitin or a-synuclein is more abundant in
iron-induced aggregates was not determined in our experiments
because the amount of antigen detected varied depending on the
method and antibody used. Anti-ubiquitin antibodies were more
sensitive than anti-a-synuclein antibodies by immunoblot, whereas
the converse was true by immunocytochemistry. Similarly, antibod-
ies to a-synuclein also displayed differential sensitivities, depend-
ing on the epitope. The monoclonal antibody directed against the
N terminus was better than the SC1 antibody in detecting aggre-
gates by immunoblotting, whereas the SC1 antibody was better than
the monoclonal antibody at detecting aggregates by immunocyto-
chemistry. The differences in sensitivity might depend on epitope
availability and have been noted by other investigators (Serpell et
al., 2000). The most parsimonious conclusion from this data is that
a-synuclein and ubiquitin are both abundant in the aggregates.
Figure 6. a-Synuclein increases iron-dependent toxicity. A, B, BE-M17
cells overexpressing wild-type, A53T, or A30P a-synuclein were treated
with varying doses of FeCl2 for 48 hr, and the viability was determined
using the MTT assay (A) or the LDH assay ( B). C, BE-M17 cells overex-
pressing wild-type, A53T, or A30P a-synuclein were treated with varying
doses of H2O2 for 48 hr, and the viability was determined using the MTT
assay. *p , 0.001, 1p , 0.01 by ANOVA analysis. D, Iron stain of BE-M17
cells. a, Untransfected cells, basal conditions; b, A53T a-synuclein-
expressing cells, basal conditions; c, untransfected cells, FeCl2–H2O2 ;
d, A53T a-synuclein-expressing cells, FeCl2–H2O2. Under basal conditions,
none of the cells showed staining for iron, but after treatment with 10 mM
FeCl2 and 100 mM H2O2 for 48 hr, the A53T cells showed much more iron
reactivity (blue, iron stain; pink, nuclear–cytoplasmic counterstain).
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One of the important questions regarding a-synuclein aggrega-
tion and Lewy body formation is whether these processes harm the
cell. Lewy bodies could be inert tombstone markers that occur in
response to free radical damage, or they might be toxic agents that
harm the cell. Examples of both situations exist in the literature.
Aggregated Ab is toxic to neurons, whereas the lipofuscin appears
to be innocuous to cells (Behl et al., 1994). The Huntingtin protein
presents an intermediate situation in which the toxicity associated
with Huntingtin appears to precede aggregation, and aggregation
of Huntingtin might even be protective (Saudou et al., 1998). Our
previous studies showed that transient overexpression of a-synuclein
is toxic to a variety of cells, including two neuronal cell lines,
SK-NSH and PC12 (Ostrerova et al., 1999). Consistent with this
observation, Masliah et al. (2000) have shown recently that mice
overexpressing a-synuclein show an age-related loss of dopaminer-
gic terminals and motor impairment, which could be indicative of
toxicity. In the present study, we observed that a-synuclein in-
creases iron-mediated toxicity and that in some assays the A53T
a-synuclein construct was more toxic than the wild-type or A30P
a-synuclein constructs. The amount of toxicity induced by each
construct generally reflects the tendency to induce aggregation.
These data suggest that a-synuclein can be harmful to neurons
under conditions that induce its aggregation.
Recent studies on transgenic animals also suggest that aggrega-
tion of a-synuclein is harmful to neurons. Masliah et al. (2000)
noted dopaminergic dysfunction in transgenic mice expressing
wild-type human a-synuclein. Even stronger effects were observed
in Drosophila overexpressing a-synuclein. Feany and Bender (2000)
observed dopaminergic dysfunction and dopaminergic neuronal
death associated with development of a-synuclein aggregates.
Thus, increasing evidence suggests that neurons with dopamine
develop a-synuclein aggregates and degenerate as these aggregates
develop.
The potential significance of these data is clear. Although the
deposits we report here are not Lewy bodies, it is remarkable that
they resemble these structures in many of their apparent constitu-
ents and are more prone to form in cells bearing pathogenic
mutations. This suggests that they may be imperfect markers of the
same processes that lead to Lewy bodies in vivo. The data we
present here link familial mutations in a-synuclein with iron and
aggregation and suggest that the pathogenic process in PD involves
the pushing of a-synuclein protein across a threshold into cellular
aggregates, which are, directly or indirectly, toxic to the cells that
contain them. Pathogenic a-synuclein mutations appear to lower
that threshold in vitro and, as we show here, a-synuclein overex-
pression and oxidative stress can also both push transfected cells
over this threshold. From a therapeutic standpoint, these data
suggest that antioxidants and agents that lead to reduction of
a-synuclein expression are legitimate targets for therapy and that
other causes of PD, whether genetic or environmental, will directly
interact with a-synuclein metabolism.
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